Cortechs.ai | A word from the CEO: 2015 in review

A word from the CEO: 2015 in review

NeuroQuant_2015_infographic1.png2015 was an incredible year for Cortechs.ai, with the team continuing to build on the momentum we started in 2014. During the year, we experienced remarkable growth in our business, added many significant new customers and expanded our strategic business partnerships.

With over 100,000 brains analyzed using NeuroQuant, it is exciting to watch the growth indicating an increased acceptance and realized importance of using quantitative imaging for the assessment of neurological disorders. During 2015, we established NeuroQuant as the most proven and most accurate quantitative imaging solutions and enjoyed worldwide support within hospitals, universities, radiology centers, clinical and research practices and military hospitals. These facilities see and understand the value of NeuroQuant’s volumetric measurements of subcortical structures aiding in the assessment of a variety of clinical disciplines, from dementia, through epilepsy, multiple sclerosis, traumatic brain injuries and brain development.

In the middle of 2015 we released NeuroQuant 2.0, providing significant additions and improvements, among them, new and improved output reports for ages 3 years to 100, the advanced Dynamic Atlas™ segmentation and registration technology, increased accuracy and precision of brain segmentation, and operating system independence. Toward the end of 2015, we expanded NeuroQuant 2.0 to include productivity enhancing capabilities such as the use of parallel imaging on GE, Philips and Siemens 3.0 T scanners, providing faster scan times, the addition of Toshiba Titan 3T scanner compatibility and PowerScribe 360 integration. Click on the infographic to the right to see a better overall picture of 2015’s developments

With these expanded capabilities NeuroQuant continues to be the paramount solution for the assessment of neurological conditions. From brain development to Alzheimer’s, multiple sclerosis, epilepsy and brain trauma, NeuroQuant helps enhance the quality of patient care. As always, we welcome feedback and ideas for improvement from anybody that wants to share it with us.

2015 was a great year, and we are thrilled to see what unfolds for 2016. Stay tuned – more exciting developments are happening and we look forward to sharing them with you!

Guri Stark, CEO
Cortechs.ai

More Resources

10/15/2025

Sharper Screening, Smarter Biopsies: OnQ Prostate and the Next Step in Imaging

Read to learn how OnQ Prostate goes beyond existing solutions like DynaCAD and redefines biopsy precision

10/14/2025

Cortechs.ai Acquires ZepMed to Expand AI-Powered Neuroimaging Capabilities

This strategic acquisition strengthens Cortechs.ai’s position at the forefront of radiological innovation and expands its suite of best-in-class solutions

10/07/2025

Cortechs.ai Expands Partnership with Strategic Radiology to Advance Imaging Innovation Across Private Practices

Cortechs.ai and Strategic Radiology have now broadened their alliance to include Cortechs.ai’s full suite of imaging solutions.

10/06/2025

Clinical Performance of NeuroQuant: Transforming Brain MRI Analysis

NeuroQuant has consistently demonstrated strong clinical performance across multiple conditions, including Alzheimer’s , epilepsy, TBI, and MS.

10/02/2025

WEBINAR: Navigating Category III CPT Codes for Quantitative Imaging

Leveraging Compatible CPT Codes for NeuroQuant and OnQ Prostate

09/29/2025

The Role of NeuroQuant in Supporting Alzheimer’s Disease Care

NeuroQuant equips clinicians and researchers with data that can support earlier recognition of disease, track progression, and evaluate treatment efficacy.
Scroll to Top